FDA delays PDUFA date for Rocket’s rare white blood cell disorder gene therapy
The FDA’s decision on Rocket Pharmaceuticals’ autologous gene therapy for a rare white blood cell disorder has been pushed back by three months to June 30 to give the agency more time to review its chemistry manufacturing and controls.
The company’s stock $RCKT was down 4% on Tuesday after the market opened. The experimental therapy, RP-L201, previously had a PDUFA date of March 31 for leukocyte adhesion deficiency-I (LAD-I).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
